Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level.

2.50
Hdl Handle:
http://hdl.handle.net/10033/210491
Title:
Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level.
Authors:
Giagulli, Cinzia; Noerder, Miriam; Avolio, Manuela; Becker, Pablo D; Fiorentini, Simona; Guzman, Carlos A; Caruso, Arnaldo
Abstract:
Mucosal dendritic cells (DCs) are very important in the process of antigen presentation to T cells, playing a key role in the induction of primary and secondary immune responses. Pidotimod is a synthetic substance capable of modulating immune cell functions, but the effect of pidotimod on human DCs has not been investigated yet. Here we demonstrate the ability of pidotimod to induce DC maturation and up-regulate the expression of HLA-DR and co-stimulatory molecules CD83 and CD86, which are fundamental for communication with adaptative immunity cells. Pidotimod also stimulated DCs to release high amounts of pro-inflammatory molecules such as MCP-1 and TNF-alpha cytokines and to drive T cell proliferation and differentiation towards a Th1 phenotype. Moreover, we demonstrate that pidotimod in vivo promotes strong and specific humoral and cellular immune response when co-administered intranasally with a model antigen. Taken together our data suggest the possibility to use pidotimod as adjuvant molecule to facilitate the activation of the innate immune system as well as to promote an effective mucosal and systemic immune response.
Affiliation:
Department of Experimental and Applied Medicine, Section of Microbiology, University of Brescia, Medical School, Brescia, Italy.
Citation:
Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level. 2009, 9 (12):1366-73 Int. Immunopharmacol.
Journal:
International immunopharmacology
Issue Date:
Nov-2009
URI:
http://hdl.handle.net/10033/210491
DOI:
10.1016/j.intimp.2009.08.010
PubMed ID:
19712757
Type:
Article
Language:
en
ISSN:
1878-1705
Appears in Collections:
publications of the research group vaccinology and applied microbiology (VAC)

Full metadata record

DC FieldValue Language
dc.contributor.authorGiagulli, Cinziaen
dc.contributor.authorNoerder, Miriamen
dc.contributor.authorAvolio, Manuelaen
dc.contributor.authorBecker, Pablo Den
dc.contributor.authorFiorentini, Simonaen
dc.contributor.authorGuzman, Carlos Aen
dc.contributor.authorCaruso, Arnaldoen
dc.date.accessioned2012-02-10T15:36:17Z-
dc.date.available2012-02-10T15:36:17Z-
dc.date.issued2009-11-
dc.identifier.citationPidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level. 2009, 9 (12):1366-73 Int. Immunopharmacol.en
dc.identifier.issn1878-1705-
dc.identifier.pmid19712757-
dc.identifier.doi10.1016/j.intimp.2009.08.010-
dc.identifier.urihttp://hdl.handle.net/10033/210491-
dc.description.abstractMucosal dendritic cells (DCs) are very important in the process of antigen presentation to T cells, playing a key role in the induction of primary and secondary immune responses. Pidotimod is a synthetic substance capable of modulating immune cell functions, but the effect of pidotimod on human DCs has not been investigated yet. Here we demonstrate the ability of pidotimod to induce DC maturation and up-regulate the expression of HLA-DR and co-stimulatory molecules CD83 and CD86, which are fundamental for communication with adaptative immunity cells. Pidotimod also stimulated DCs to release high amounts of pro-inflammatory molecules such as MCP-1 and TNF-alpha cytokines and to drive T cell proliferation and differentiation towards a Th1 phenotype. Moreover, we demonstrate that pidotimod in vivo promotes strong and specific humoral and cellular immune response when co-administered intranasally with a model antigen. Taken together our data suggest the possibility to use pidotimod as adjuvant molecule to facilitate the activation of the innate immune system as well as to promote an effective mucosal and systemic immune response.en
dc.language.isoenen
dc.subject.meshAdjuvants, Immunologicen
dc.subject.meshAnimalsen
dc.subject.meshAntibody Formationen
dc.subject.meshAntigens, CDen
dc.subject.meshCell Differentiationen
dc.subject.meshCell Proliferationen
dc.subject.meshCells, Cultureden
dc.subject.meshChemokine CCL2en
dc.subject.meshCytotoxicity, Immunologicen
dc.subject.meshDendritic Cellsen
dc.subject.meshFemaleen
dc.subject.meshHLA-DR Antigensen
dc.subject.meshHumansen
dc.subject.meshLymphocyte Activationen
dc.subject.meshMiceen
dc.subject.meshMice, Inbred C57BLen
dc.subject.meshNasal Mucosaen
dc.subject.meshOvalbuminen
dc.subject.meshPeptide Fragmentsen
dc.subject.meshPyrrolidonecarboxylic Aciden
dc.subject.meshTh1 Cellsen
dc.subject.meshThiazolidinesen
dc.subject.meshTumor Necrosis Factor-alphaen
dc.titlePidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level.en
dc.typeArticleen
dc.contributor.departmentDepartment of Experimental and Applied Medicine, Section of Microbiology, University of Brescia, Medical School, Brescia, Italy.en
dc.identifier.journalInternational immunopharmacologyen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.